Compare 10X Genomics Inc (TXG) vs Consumer Discretionary Select Sector SPDR Fund (XLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
10X Genomics Inc vs Consumer Discretionary Select Sector SPDR Fund — how do they compare? 10X Genomics Inc trades at $67.59 (market cap $8.55B), while Consumer Discretionary Select Sector SPDR Fund trades at $112.59. The key difference: 10X Genomics Inc is trading nearer its 52-week high, Consumer Discretionary Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals.
| TXG | XLY | |
|---|---|---|
Market Cap | $8.55B | — |
Sector | Health | — |
52-Week High | $67.29 | $124.52 |
52-Week Low | $11.34 | $105.64 |
Enterprise Value | $8.08B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TXG trades at $65.60, up 4.71% today, with strong technical momentum showing bullish moving averages and key support at $63. Fundamentally, the company demonstrates improving trends with Q2 2026 earnings beating estimates and revenue growth guidance raised, though profitability remains negative with a -12.18% net margin. Recent patent victory against Parse Biosciences strengthens competitive positioning.
The outlook remains cautiously optimistic with analyst consensus at 45% buy ratings and $50.78 price target. Key opportunities include Atera platform adoption and consumables growth, while risks center on valuation premiums and ongoing profitability challenges. The stock trades near resistance at $67 with institutional interest showing mixed signals.
XLY trades at $113.99, down 0.8% on the day, with technical indicators showing a bearish trend as moving averages signal strong selling pressure. The ETF maintains 100% analyst buy ratings, reflecting confidence in consumer discretionary exposure despite current market weakness. Recent news highlights XLY as a potential sleeper opportunity for Q3 2026, with consumer spending trends supporting the sector's long-term prospects.
The outlook remains constructive given unanimous analyst support and consumer resilience, though technical weakness and sector concentration risks require monitoring. Upside potential exists if consumer discretionary spending accelerates, while economic slowdowns could pressure performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →About Consumer Discretionary Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: retail; hotels, restaurants and leisure; textiles, apparel and luxury goods; household durables; automobiles; auto components; distributors; leisure products; and diversified consumer services. It is non-diversified.
Read more on XLY →
